1. Home
  2. MUA vs ALT Comparison

MUA vs ALT Comparison

Compare MUA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MUA
  • ALT
  • Stock Information
  • Founded
  • MUA 1993
  • ALT 1997
  • Country
  • MUA United States
  • ALT United States
  • Employees
  • MUA N/A
  • ALT N/A
  • Industry
  • MUA Investment Bankers/Brokers/Service
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • MUA Finance
  • ALT Health Care
  • Exchange
  • MUA Nasdaq
  • ALT Nasdaq
  • Market Cap
  • MUA 396.8M
  • ALT 472.3M
  • IPO Year
  • MUA N/A
  • ALT N/A
  • Fundamental
  • Price
  • MUA $10.49
  • ALT $4.76
  • Analyst Decision
  • MUA
  • ALT Strong Buy
  • Analyst Count
  • MUA 0
  • ALT 6
  • Target Price
  • MUA N/A
  • ALT $20.20
  • AVG Volume (30 Days)
  • MUA 92.6K
  • ALT 11.3M
  • Earning Date
  • MUA 01-01-0001
  • ALT 08-07-2025
  • Dividend Yield
  • MUA 4.84%
  • ALT N/A
  • EPS Growth
  • MUA N/A
  • ALT N/A
  • EPS
  • MUA N/A
  • ALT N/A
  • Revenue
  • MUA N/A
  • ALT $20,000.00
  • Revenue This Year
  • MUA N/A
  • ALT N/A
  • Revenue Next Year
  • MUA N/A
  • ALT $1,557,547.90
  • P/E Ratio
  • MUA N/A
  • ALT N/A
  • Revenue Growth
  • MUA N/A
  • ALT N/A
  • 52 Week Low
  • MUA $8.61
  • ALT $2.90
  • 52 Week High
  • MUA $11.43
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • MUA 69.72
  • ALT 42.91
  • Support Level
  • MUA $10.21
  • ALT $3.30
  • Resistance Level
  • MUA $10.26
  • ALT $7.73
  • Average True Range (ATR)
  • MUA 0.08
  • ALT 0.59
  • MACD
  • MUA 0.04
  • ALT -0.27
  • Stochastic Oscillator
  • MUA 95.00
  • ALT 38.51

About MUA Blackrock MuniAssets Fund Inc

Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: